Melissa E. Petersen, Ph.D.
Permanent URI for this communityhttps://hdl.handle.net/20.500.12503/31202
Assistant Professor, Family Medicine and Osteopathic Manipulative Medicine
Email: Melissa.Petersen@unthsc.edu
Browse
Browsing Melissa E. Petersen, Ph.D. by Author "Handen, Benjamin"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Item Acute Regression in Down Syndrome(MDPI, 2021-08-23) Handen, Benjamin; Clare, Isabel; Laymon, Charles; Petersen, Melissa E.; Zaman, Shahid; O'Bryant, Sid E.; Minhas, Davneet; Tudorascu, Dana; Brown, Stephanie; Christian, BradleyAcute regression has been reported in some individuals with Down syndrome (DS), typically occurring between the teenage years and mid to late 20s. Characterized by sudden, and often unexplained, reductions in language skills, functional living skills and reduced psychomotor activity, some individuals have been incorrectly diagnosed with Alzheimer's disease (AD).|This paper compares five individuals with DS who previously experienced acute regression with a matched group of 15 unaffected individuals with DS using a set of AD biomarkers.|While the sample was too small to conduct statistical analyses, findings suggest there are possible meaningful differences between the groups on proteomics biomarkers (e.g., NfL, total tau). Hippocampal, caudate and putamen volumes were slightly larger in the regression group, the opposite of what was hypothesized. A slightly lower amyloid load was found on the PET scans for the regression group, but no differences were noted on tau PET.|Some proteomics biomarker findings suggest that individuals with DS who experience acute regression may be at increased risk for AD at an earlier age in comparison to unaffected adults with DS. However, due to the age of the group (mean 38 years), it may be too early to observe meaningful group differences on image-based biomarkers.Item Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) study(Wiley Periodicals, Inc., 2020-06-30) Petersen, Melissa E.; Zhang, Fan; Schupf, Nicole; Krinsky-McHale, Sharon J.; Hall, James R.; Mapstone, Mark; Cheema, Amrita; Silverman, Wayne; Lott, Ira; Rafii, Michael S.; Handen, Benjamin; Klunk, William; Head, Elizabeth; Christian, Bradley; Foroud, Tatiana; Lai, Florence; Rosas, H. Diana; Zaman, Shahid; Ances, Beau M.; Wang, Mei-Cheng; Tycko, Benjamin; Lee, Joseph H.; O'Bryant, Sid E.Introduction: Previously generated serum and plasma proteomic profiles were examined among adults with Down syndrome (DS) to determine whether these profiles could discriminate those with mild cognitive impairment (MCI-DS) and Alzheimer's disease (DS-AD) from those cognitively stable (CS). Methods: Data were analyzed on n = 305 (n = 225 CS; n = 44 MCI-DS; n = 36 DS-AD) enrolled in the Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS). Results: Distinguishing MCI-DS from CS, the serum profile produced an area under the curve (AUC) = 0.95 (sensitivity [SN] = 0.91; specificity [SP] = 0.99) and an AUC = 0.98 (SN = 0.96; SP = 0.97) for plasma when using an optimized cut-off score. Distinguishing DS-AD from CS, the serum profile produced an AUC = 0.93 (SN = 0.81; SP = 0.99) and an AUC = 0.95 (SN = 0.86; SP = 1.0) for plasma when using an optimized cut-off score. AUC remained unchanged to slightly improved when age and sex were included. Eotaxin3, interleukin (IL)-10, C-reactive protein, IL-18, serum amyloid A , and FABP3 correlated fractions at r2 > = 0.90. Discussion: Proteomic profiles showed excellent detection accuracy for MCI-DS and DS-AD.